GTN is a London-based company developing a drug discovery platform built around its patented Generative Tensorial Networks technology, which facilitates the search for novel small-molecule drugs from unexplored domains. Led by Co-Founder and CEO Professor Noor Shaker, the company runs collaborations with global pharmaceutical companies and has partnerships with research bodies including the Francis Crick Institute. The company raised £2.1m ($3m) in seed funding. It intends to use the funds to recruit for roles within Machine Learning, Computational Chemistry and Drug Discovery. GTN's platform and partnerships support its research and development activities. Entrepreneur First is an existing investor that participated in the round.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

May 2018